Tricida (NASDAQ: TCDA) is a pharmaceutical company that is focused on developing and commercializing its drug Veverimer for the treatment of metabolic acidosis in patients with CKD (chronic kidney disease).  Tricida stock is in the spotlight due to the sudden spike in insider trades in June. Trades in Detail  Per Tricida’s SEC filings and TipRanks’ Insider Trading Activity tool, Venrock Healthcare Capital Partners, which owns more than a 10% stake in the company, has been accumulating its stock. Venrock Healthcare acquired shares worth more than $13 million this month.
https://www.tipranks.com/news/article/heres-what-to-infer-from-tricidas-insider-trades?utm_source=advfn.com&utm_medium=referral
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Out 2022 até Nov 2022 Click aqui para mais gráficos Tricida.
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Nov 2021 até Nov 2022 Click aqui para mais gráficos Tricida.